Journal article
Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis
Abstract
BACKGROUND: Nintedanib is an approved treatment for idiopathic pulmonary fibrosis (IPF). A subgroup analysis of a previously published trial suggested that sildenafil may provide benefits regarding oxygenation, gas exchange as measured by the diffusion capacity of the lungs for carbon monoxide (DlCO), symptoms, and quality of life in patients with IPF and severely decreased DlCO. That idea was tested in this trial.
METHODS: We randomly …
Authors
Kolb M; Raghu G; Wells AU; Behr J; Richeldi L; Schinzel B; Quaresma M; Stowasser S; Martinez FJ
Journal
New England Journal of Medicine, Vol. 379, No. 18, pp. 1722–1731
Publisher
Massachusetts Medical Society
Publication Date
November 2018
DOI
10.1056/nejmoa1811737
ISSN
0028-4793